← FDA DRUG APPROVALS

FDA ANDA · ANDA204696

LINEZOLID

Sponsor: SAGENT PHARMS INC

APPLICATION
ANDA204696
TYPE
ANDA
ORIGINAL APPROVAL
2017-03-02
LATEST ACTION
2024-02-28
ROUTE
INTRAVENOUS
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription

Products

LINEZOLIDPrescription
LINEZOLID 200MG/100ML (2MG/ML) · SOLUTION · INTRAVENOUS
LINEZOLIDPrescription
LINEZOLID 600MG/300ML (2MG/ML) · SOLUTION · INTRAVENOUS

Approval history

2024-02-28Labeling · Supplement 11 · standardAP
2024-02-28Labeling · Supplement 8 · standardAP
2024-02-28Labeling · Supplement 10 · standardAP
2019-06-28Labeling · Supplement 2 · standardAP
2017-03-02UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →